文献速递乳腺乳腺X线US

乳腺X线与超声对症状性男性乳腺病变的诊断准确性:PRISMA-DTA系统综述与Meta分析

Mammography and Ultrasonography for Symptomatic Male Breast Lesions: A PRISMA-DTA Systematic Review and Meta-analysis.
PubMed 文献 · Acad Radiol · 2026-10-15

该PRISMA-DTA系统综述与Meta分析纳入13篇报告,分别合并7个乳腺X线数据集和5个超声数据集,评估二者鉴别男性乳腺良恶性病变的准确性。乳腺X线合并敏感度0.840、特异度0.951;超声合并敏感度0.881、特异度0.958。9/13篇报告总体偏倚风险高,缺乏配对头对头数据,现有证据不支持任一模态的直接优越性,也不能据此避免活检或确定常规联合成像的增量价值。

要点

  • 症状性男性乳腺病变中,乳腺X线与超声合并特异度均高,但敏感度中等,阴性不能完全排除恶性。
  • 现有证据方法学质量有限,9/13篇报告偏倚风险高,合并估计需谨慎解读。
  • 临床与影像不一致时,现有数据不支持仅凭影像避免活检。

核心结论

  • 现有证据支持乳腺X线和超声作为症状性男性乳腺病变风险分层评估的互补工具。
  • 合并估计应谨慎解读,因证据基础小且方法学受限。
  • 当前数据未确立任一模态的直接优越性。
  • 当前数据不支持在临床-影像不一致持续存在时避免活检。
  • 当前数据未确定常规联合成像的增量价值。

研究设计与样本

  • PRISMA-DTA系统综述与Meta分析,方案在PROSPERO注册(CRD420261429183)。
  • 检索PubMed、Embase、Web of Science核心合集和Scopus,从建库至2026年5月30日。
  • 纳入13篇符合条件报告,其中7个乳腺X线数据集和5个超声数据集可用于定量合成。
  • 方法学质量采用QUADAS-2评估,9/13篇报告总体偏倚风险高。
  • 采用双变量随机效应模型和汇总受试者工作特征分析分别合并各模态诊断准确性。

诊断标准与关键数值

  • 乳腺X线鉴别男性乳腺恶性 vs 良性病变:合并敏感度0.840(95%CI 0.705-0.921),合并特异度0.951(95%CI 0.884-0.980)。
  • 超声鉴别男性乳腺恶性 vs 良性病变:合并敏感度0.881(95%CI 0.775-0.941),合并特异度0.958(95%CI 0.869-0.987)。
  • 合并特异度估计虽高,但其幅度可能受异质性诊断阈值、差异化验证、随访变异和恶性病例数稀少影响。
  • 缺乏一致的头对头配对数据,无法直接比较两种模态的准确性。

临床应用与阅片要点

  • 对症状性男性乳腺病变,可将乳腺X线和超声作为互补工具进行风险分层评估。
  • 影像阴性时需结合临床,因合并敏感度非极高,不能完全排除恶性。
  • 临床与影像不一致持续存在时,不应仅凭影像避免活检。
  • 常规联合成像的增量价值尚未确定,联合决策需个体化。
  • 解读合并特异度时需考虑诊断阈值异质性和恶性病例稀疏的影响。

局限性

  • 证据基础小,仅纳入13篇报告。
  • 9/13篇报告总体偏倚风险高。
  • 缺乏一致的头对头配对数据。
  • 合并特异度可能受异质性诊断阈值、差异化验证和随访变异影响。
  • 恶性病例数稀疏可能影响合并估计的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Male breast disease is uncommon, but symptomatic men require reliable differentiation between benign conditions and lesions warranting biopsy or oncologic management. This PRISMA-DTA (Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies) systematic review and meta-analysis evaluated the diagnostic accuracy, clinical utility, and evidentiary limitations of mammography and ultrasonography for malignant versus benign male breast lesions.

MATERIALS AND METHODS: PubMed, Embase, Web of Science Core Collection, and Scopus were searched from inception to May 30, 2026. The protocol was registered in PROSPERO before journal submission (CRD420261429183). Eligible reports evaluated mammography or ultrasonography in male breast disease and provided extractable 2 × 2 diagnostic data. Methodological quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. Diagnostic accuracy was synthesized separately for each modality using bivariate random-effects modeling and summary receiver operating characteristic analysis.

RESULTS: Thirteen eligible reports were included. Seven mammography datasets and five ultrasonography datasets were available for quantitative synthesis. Mammography showed a pooled sensitivity of 0.840 (95% confidence interval [CI], 0.705-0.921) and a specificity of 0.951 (95% CI, 0.884-0.980), whereas ultrasonography showed a pooled sensitivity of 0.881 (95% CI, 0.775-0.941) and a specificity of 0.958 (95% CI, 0.869-0.987). Although pooled specificity estimates were high, their magnitude may have been influenced by heterogeneous diagnostic thresholds, differential verification, variable follow-up, and sparse malignant case counts. Nine of 13 reports were judged to have an overall high risk of bias, and consistent paired head-to-head data were lacking.

CONCLUSION: Current evidence supports mammography and ultrasonography as complementary tools in risk-stratified assessment of symptomatic male breast lesions. Pooled estimates should be interpreted cautiously because the evidence base is small and methodologically limited. Current data do not establish direct modality superiority, do not justify biopsy avoidance when clinical-imaging discordance persists, and do not determine the incremental value of routine combined imaging.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang C, Liu X, Yan C, et al. Mammography and Ultrasonography for Symptomatic Male Breast Lesions: A PRISMA-DTA Systematic Review and Meta-analysis. Acad Radiol. 2026. PMID: 42881007. doi:10.1016/j.acra.2026.09.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。